GlassScriptPhysician profile
Riccardo Lencioni
NPI 1972976579
$29,975.37
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $7,975.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,228.58 | 2019-2020 | |
| Eisai Co., LTD. | $6,900.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,100.00 | 2021 | |
| F. Hoffmann-La Roche Ag | $4,076.97 | 2019 | |
| Eisai INC. | $1,875.00 | 2021 | |
| Astrazeneca Uk Limited | $639.80 | 2019 | |
| Angiodynamics, INC. | $155.02 | 2019-2020 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$5,800.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riccardo Lencioni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.